Brokerage firm H.C. Wainwright Assumes its rating on Capricor Therapeutics Inc(NASDAQ:CAPR). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Jul 6, 2016.
In a different note, Roth Capital said it Initiates Coverage on Capricor Therapeutics Inc, according to a research note issued on Jun 15, 2016. The shares have been rated ‘Buy’ by the firm.
Capricor Therapeutics Inc (CAPR) made into the market gainers list on Mondays trading session with the shares advancing 1.99% or 0.08 points. Due to strong positive momentum, the stock ended at $4.1, which is also near the day’s high of $4.24. The stock began the session at $4.1994 and the volume stood at 8,373 shares. The 52-week high of the shares is $5.4 and the 52 week low is $1.88. The company has a current market capitalization of $74 M and it has 1,79,52,323 shares in outstanding.
Capricor Therapeutics Inc(CAPR) last announced its earnings results on May 12, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.22M. Analysts had an estimated revenue of $1.10M. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.19.
Several Insider Transactions has been reported to the SEC. On Mar 21, 2016, Sinai Medical Center Cedars (10% owner) purchased 416,666 shares at $2.40 per share price.Also, On Mar 21, 2016, Linda Marban (CEO) purchased 10,152 shares at $2.40 per share price.On Mar 21, 2016, Anthony Bergmann (Vice President of Finance) purchased 2,030 shares at $2.40 per share price, according to the Form-4 filing with the securities and exchange commission.
Capricor Therapeutics Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development which include CAP-1002 CAP-1001 CSps Exosomes Cenderitide (CD-NP) and CU-NP. The Company’s technology is based in cardiospheres (CSps) which are multi-cell clusters of cardiac derived cells. The Company’s product candidate the cardiosphere-derived cells (CDC) is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).